Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans
Blockbuster Status In Sight For Pfizer Drug
Executive Summary
Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.
You may also be interested in...
Alnylam Wins FDA Approval For Givlaari, Its Second RNAi Drug
Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly three months ahead of the action date.
Moderna Files COVID-19 Vaccine After Second Impressive Read-Out
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports